Mixtard 30 Innolet (Insulin Human)

Insulin human mimics the body’s natural insulin, binding to insulin receptors on cells. This triggers pathways that increase glucose uptake into muscle and fat, promote glycogen storage in the liver, and suppress glucose production, thereby lowering circulating blood sugar.

The dose of Mixtard 30 Innolet is individualized. A qualified prescriber determines the amount based on the patient’s blood‑glucose monitoring, dietary intake, activity level, and overall treatment goals.

Insulin is generally considered the preferred glucose‑lowering therapy in pregnancy when needed. However, the decision to use Mixtard 30 Innolet should be made by a healthcare professional after weighing potential benefits and risks for both mother and fetus. Breastfeeding mothers should also consult their provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Mixtard 30 Innolet combines rapid‑acting and intermediate‑acting insulin in a single pen, offering flexibility for both mealtime and basal coverage. Compared with basal‑only insulins, it reduces the number of injections needed, while providing a more predictable pharmacokinetic profile than some mixed‑insulin preparations.

Store the pen at 2‑8 °C (refrigerated) and protect it from light. Do not freeze or shake the pen. Once in use, it may be kept at room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

Mixtard 30 Innolet is administered subcutaneously using the prefilled pen. The injection site should be rotated among the abdomen, thigh, or upper arm. Patients should follow the prescriber’s instructions on dosing timing relative to meals.

The most serious risks include severe hypoglycaemia, which can lead to seizures or loss of consciousness, and allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical help if a severe reaction occurs.

Mixtard 30 Innolet should not be used by individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycaemia until the condition is corrected.